- Home
- NXP vs PRME Comparison
NXP vs PRME Comparison
Compare NXP & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXP
- PRME
- Stock Information
- Founded
- NXP 1992
- PRME 2019
- Country
- NXP United States
- PRME United States
- Employees
- NXP N/A
- PRME N/A
- Industry
- NXP Trusts Except Educational Religious and Charitable
- PRME Medicinal Chemicals and Botanical Products
- Sector
- NXP Finance
- PRME Health Care
- Exchange
- NXP Nasdaq
- PRME Nasdaq
- Market Cap
- NXP 744.2M
- PRME 601.1M
- IPO Year
- NXP N/A
- PRME 2022
- Fundamental
- Price
- NXP $14.32
- PRME $3.75
- Analyst Decision
- NXP
- PRME Buy
- Analyst Count
- NXP 0
- PRME 6
- Target Price
- NXP N/A
- PRME $9.31
- AVG Volume (30 Days)
- NXP 70.0K
- PRME 4.1M
- Earning Date
- NXP 01-01-0001
- PRME 11-07-2025
- Dividend Yield
- NXP 4.04%
- PRME N/A
- EPS Growth
- NXP N/A
- PRME N/A
- EPS
- NXP 0.54
- PRME N/A
- Revenue
- NXP N/A
- PRME $5,977,000.00
- Revenue This Year
- NXP N/A
- PRME $179.58
- Revenue Next Year
- NXP N/A
- PRME N/A
- P/E Ratio
- NXP $26.81
- PRME N/A
- Revenue Growth
- NXP N/A
- PRME 647.13
- 52 Week Low
- NXP $12.91
- PRME $1.11
- 52 Week High
- NXP $14.89
- PRME $6.94
- Technical
- Relative Strength Index (RSI)
- NXP 44.41
- PRME 42.91
- Support Level
- NXP $14.20
- PRME $3.43
- Resistance Level
- NXP $14.49
- PRME $4.04
- Average True Range (ATR)
- NXP 0.18
- PRME 0.38
- MACD
- NXP -0.01
- PRME 0.03
- Stochastic Oscillator
- NXP 33.34
- PRME 44.88
About NXP Nuveen Select Tax Free Income Portfolio
Nuveen Select Tax Free Income Portfolio is a closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax, consistent with preservation of capital. The fund invests a majority of its assets in municipal securities and other related investments, the income from which is exempt from regular federal income tax and federal alternative minimum tax.
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.